PortalPublikationenPRECIOUS

PRECIOUS

Standard

PRECIOUS : PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. / Reinink, Hendrik; de Jonge, Jeroen C; Bath, Philip M; van de Beek, Diederik; Berge, Eivind; Borregaard, Saskia; Ciccone, Alfonso; Csiba, Laszlo; Demotes, Jacques; Dippel, Diederik W; Kõrv, Janika; Kurkowska-Jastrzebska, Iwona; Lees, Kennedy R; Macleod, Malcolm R; Ntaios, George; Randall, Gary; Thomalla, Götz; van der Worp, H Bart.

in: EUR STROKE J, Jahrgang 3, Nr. 3, 09.2018, S. 291-298.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reinink, H, de Jonge, JC, Bath, PM, van de Beek, D, Berge, E, Borregaard, S, Ciccone, A, Csiba, L, Demotes, J, Dippel, DW, Kõrv, J, Kurkowska-Jastrzebska, I, Lees, KR, Macleod, MR, Ntaios, G, Randall, G, Thomalla, G & van der Worp, HB 2018, 'PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment', EUR STROKE J, Jg. 3, Nr. 3, S. 291-298. https://doi.org/10.1177/2396987318772687

APA

Reinink, H., de Jonge, J. C., Bath, P. M., van de Beek, D., Berge, E., Borregaard, S., Ciccone, A., Csiba, L., Demotes, J., Dippel, D. W., Kõrv, J., Kurkowska-Jastrzebska, I., Lees, K. R., Macleod, M. R., Ntaios, G., Randall, G., Thomalla, G., & van der Worp, H. B. (2018). PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. EUR STROKE J, 3(3), 291-298. https://doi.org/10.1177/2396987318772687

Vancouver

Reinink H, de Jonge JC, Bath PM, van de Beek D, Berge E, Borregaard S et al. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. EUR STROKE J. 2018 Sep;3(3):291-298. https://doi.org/10.1177/2396987318772687

Bibtex

@article{4842ceb7a1aa4d4ea6659419ac530945,
title = "PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment",
abstract = "BACKGROUND: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence of these complications has been associated with an increased risk of death or dependency.Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly patients with acute stroke.DESIGN: International, 3 × 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment (PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an NIHSS score ≥ 6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier.Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days (± 14 days), as analysed with multiple regression.Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce the burden of death or disability in patients with stroke at very low costs.Planning: First patient included in May 2016; final follow-up of the last patient by April 2020.Registration: ISRCTN, ISRCTN82217627, https://doi.org/10.1186/ISRCTN82217627.",
author = "Hendrik Reinink and {de Jonge}, {Jeroen C} and Bath, {Philip M} and {van de Beek}, Diederik and Eivind Berge and Saskia Borregaard and Alfonso Ciccone and Laszlo Csiba and Jacques Demotes and Dippel, {Diederik W} and Janika K{\~o}rv and Iwona Kurkowska-Jastrzebska and Lees, {Kennedy R} and Macleod, {Malcolm R} and George Ntaios and Gary Randall and G{\"o}tz Thomalla and {van der Worp}, {H Bart}",
year = "2018",
month = sep,
doi = "10.1177/2396987318772687",
language = "English",
volume = "3",
pages = "291--298",
journal = "EUR STROKE J",
issn = "2396-9873",
publisher = "SAGE Publications",
number = "3",

}

RIS

TY - JOUR

T1 - PRECIOUS

T2 - PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment

AU - Reinink, Hendrik

AU - de Jonge, Jeroen C

AU - Bath, Philip M

AU - van de Beek, Diederik

AU - Berge, Eivind

AU - Borregaard, Saskia

AU - Ciccone, Alfonso

AU - Csiba, Laszlo

AU - Demotes, Jacques

AU - Dippel, Diederik W

AU - Kõrv, Janika

AU - Kurkowska-Jastrzebska, Iwona

AU - Lees, Kennedy R

AU - Macleod, Malcolm R

AU - Ntaios, George

AU - Randall, Gary

AU - Thomalla, Götz

AU - van der Worp, H Bart

PY - 2018/9

Y1 - 2018/9

N2 - BACKGROUND: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence of these complications has been associated with an increased risk of death or dependency.Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly patients with acute stroke.DESIGN: International, 3 × 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment (PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an NIHSS score ≥ 6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier.Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days (± 14 days), as analysed with multiple regression.Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce the burden of death or disability in patients with stroke at very low costs.Planning: First patient included in May 2016; final follow-up of the last patient by April 2020.Registration: ISRCTN, ISRCTN82217627, https://doi.org/10.1186/ISRCTN82217627.

AB - BACKGROUND: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence of these complications has been associated with an increased risk of death or dependency.Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly patients with acute stroke.DESIGN: International, 3 × 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment (PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an NIHSS score ≥ 6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier.Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days (± 14 days), as analysed with multiple regression.Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce the burden of death or disability in patients with stroke at very low costs.Planning: First patient included in May 2016; final follow-up of the last patient by April 2020.Registration: ISRCTN, ISRCTN82217627, https://doi.org/10.1186/ISRCTN82217627.

U2 - 10.1177/2396987318772687

DO - 10.1177/2396987318772687

M3 - SCORING: Journal article

C2 - 30246150

VL - 3

SP - 291

EP - 298

JO - EUR STROKE J

JF - EUR STROKE J

SN - 2396-9873

IS - 3

ER -